On Jun. 19, 2020, Dynavax Technologies announced the first participants were dosed in the Phase 1 clinical trial to evaluate Clover Biopharmaceuticalsﾒ vaccine candidate to prevent COVID-19 that contains the Companyﾒs CpG 1018 adjuvant.

Clover is advancing its COVID-19 S-Trimer vaccine (SCB-2019), which is based on Cloverﾒs proprietary Trimer-Tagﾩ vaccine technology platform, while Dynavax is providing the Companyﾒs proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018.